$ELOX
Eloxx Pharmaceuticals, Inc.

2014 Q2 Form 10-Q Financial Statement

#000114420414029005 Filed on May 09, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $450.0K $1.170M $480.0K
YoY Change 9.76% 143.75% -4.0%
% of Gross Profit
Research & Development $1.090M $966.3K $492.9K
YoY Change 122.45% 96.07% -8.86%
% of Gross Profit
Depreciation & Amortization $110.0K $90.00K $70.00K
YoY Change 22.22% 28.57% 0.0%
% of Gross Profit
Operating Expenses $1.640M $966.3K $492.9K
YoY Change 65.66% 96.07% -8.86%
Operating Profit -$2.129M -$1.044M
YoY Change 103.87% -5.81%
Interest Expense $0.00 -$17.81K -$19.85K
YoY Change -100.0% -10.26% -29.06%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$3.670M -$2.150M -$840.0K
YoY Change 90.16% 155.95% -20.75%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.670M -$2.147M -$836.6K
YoY Change 90.16% 156.61% -21.13%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$7.058M -$7.414M -$12.00M
COMMON SHARES
Basic Shares Outstanding 6.906M shares 5.042M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.110M $6.200M $1.580M
YoY Change 281.88% 292.41% -50.78%
Cash & Equivalents $6.111M $6.198M $1.581M
Short-Term Investments
Other Short-Term Assets $1.070M $1.200M $1.710M
YoY Change -44.27% -29.82% -1.72%
Inventory
Prepaid Expenses $1.070M $1.200M
Receivables $43.13K
Other Receivables $0.00
Total Short-Term Assets $7.224M $7.398M $3.290M
YoY Change 105.15% 124.86% -33.44%
LONG-TERM ASSETS
Property, Plant & Equipment $223.5K $2.992K $10.00K
YoY Change 4806.15% -70.08% 54.94%
Goodwill $13.90M
YoY Change
Intangibles $2.179M $3.554M
YoY Change -38.91%
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $26.11M $3.562M $3.600M
YoY Change 630.11% -1.06% -2.49%
TOTAL ASSETS
Total Short-Term Assets $7.224M $7.398M $3.290M
Total Long-Term Assets $26.11M $3.562M $3.600M
Total Assets $33.33M $10.96M $6.890M
YoY Change 369.65% 59.07% -20.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $901.2K $324.9K $690.0K
YoY Change 41.4% -52.91% -14.26%
Accrued Expenses $924.0K $730.4K $340.0K
YoY Change 138.42% 114.82% -35.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $2.190M
YoY Change -100.0% -100.0% -0.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.825M $1.055M $3.220M
YoY Change -43.18% -67.23% -8.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $99.73K $99.73K $360.0K
YoY Change 0.0% -72.3% 260.98%
Total Long-Term Liabilities $99.73K $99.73K $360.0K
YoY Change 0.0% -72.3% 260.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.825M $1.055M $3.220M
Total Long-Term Liabilities $99.73K $99.73K $360.0K
Total Liabilities $5.845M $1.155M $3.580M
YoY Change 76.49% -67.74% -11.29%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $138.5K $68.98K
YoY Change 509.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.49M $9.800M $3.310M
YoY Change
Total Liabilities & Shareholders Equity $33.33M $10.96M $6.890M
YoY Change 369.65% 59.07% -20.2%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$3.670M -$2.147M -$836.6K
YoY Change 90.16% 156.61% -21.13%
Depreciation, Depletion And Amortization $110.0K $90.00K $70.00K
YoY Change 22.22% 28.57% 0.0%
Cash From Operating Activities -$1.220M -$1.560M -$1.760M
YoY Change 29.79% -11.36% 79.59%
INVESTING ACTIVITIES
Capital Expenditures -$220.0K -$160.0K -$140.0K
YoY Change 57.14% 14.29% 27.27%
Acquisitions
YoY Change
Other Investing Activities $1.270M
YoY Change
Cash From Investing Activities $1.060M -$160.0K -$140.0K
YoY Change -857.14% 14.29% 27.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 1.790M 2.840M
YoY Change -93.64% -36.97% 3.27%
NET CHANGE
Cash From Operating Activities -1.220M -1.560M -1.760M
Cash From Investing Activities 1.060M -160.0K -140.0K
Cash From Financing Activities 70.00K 1.790M 2.840M
Net Change In Cash -90.00K 70.00K 940.0K
YoY Change -550.0% -92.55% -43.37%
FREE CASH FLOW
Cash From Operating Activities -$1.220M -$1.560M -$1.760M
Capital Expenditures -$220.0K -$160.0K -$140.0K
Free Cash Flow -$1.000M -$1.400M -$1.620M
YoY Change 25.0% -13.58% 86.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2992 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1055321 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
7397898 USD
CY2014Q1 us-gaap Liabilities
Liabilities
1155049 USD
CY2014Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171 USD
CY2014Q1 us-gaap Assets
Assets
10959693 USD
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
324936 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
730385 USD
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6198027 USD
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1199871 USD
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3553632 USD
CY2014Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
68977 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1570891 shares
snti Unrecognized Share Based Compensation Expense
UnrecognizedShareBasedCompensationExpense
480000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P42M
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
231748 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
74080 shares
snti Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
27788 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2955 shares
CY2014Q1 snti Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock
CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock
290000 shares
CY2014Q1 snti Number Of Diluted Warrants Outstanding
NumberOfDilutedWarrantsOutstanding
3765995 shares
CY2014Q1 snti Number Of Diluted Options Outstanding
NumberOfDilutedOptionsOutstanding
275085 shares
CY2014Q1 snti Potential Dilutive Shares Of Common Stock
PotentialDilutiveSharesOfCommonStock
4331080 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
46780 shares
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
201154 USD
snti Probability To Achieve Employee Target Goals
ProbabilityToAchieveEmployeeTargetGoals
0.65 pure
CY2014Q1 snti Issuance Of Additional Options
IssuanceOfAdditionalOptions
27300 shares
snti Options Aggregated During Period
OptionsAggregatedDuringPeriod
111210 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.22
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.00
us-gaap Share Based Compensation
ShareBasedCompensation
552303 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
275085 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
200018 shares
CY2014Q1 snti Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable And Expected To Be Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndExpectedToBeExercisableNumber
253055 shares
us-gaap Share Based Compensation
ShareBasedCompensation
735977 USD
snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice
0
snti Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice
16.50
CY2014Q1 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
4.30
CY2013Q2 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
345.00
CY2014Q1 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
345.00
CY2010Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
3000000 USD
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0375 pure
CY2010Q1 snti Line Of Credit Spread Over Base Rate
LineOfCreditSpreadOverBaseRate
0.020 pure
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Line of Credit accrued at an annual interest rate of (i) the broker rate in effect at the interest date (which was 3.75% at December 31, 2013), plus (ii) 2.0% and are due on demand. There were no other conditions or fees associated with the Line of Credit.
CY2013Q1 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
20875 USD
CY2014Q1 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
21278 USD
us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
90651 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.39
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
239.74
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.86
CY2013Q2 snti Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
4.30
us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
85629 USD
CY2014Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6095392 USD
CY2013Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1469569 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6897710 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2272062 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6897710 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2272062 shares
CY2013Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2014Q1 us-gaap Licenses Revenue
LicensesRevenue
0 USD
us-gaap Licenses Revenue
LicensesRevenue
1890000 USD
us-gaap Licenses Revenue
LicensesRevenue
0 USD
us-gaap Licenses Revenue
LicensesRevenue
100000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
551424 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1253730 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37250264 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1993112 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3135963 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
492850 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
875213 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25571726 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1597362 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2249455 USD
CY2013Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2014Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2158595 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
1044274 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1632838 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
201911 USD
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
2128943 USD
us-gaap Costs And Expenses
CostsAndExpenses
64980585 USD
us-gaap Costs And Expenses
CostsAndExpenses
3590474 USD
us-gaap Costs And Expenses
CostsAndExpenses
5570579 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1044274 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2128943 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-63090585 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3590474 USD
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
244479 USD
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2013Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
227539 USD
CY2014Q1 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
8701721 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
271831 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0 USD
CY2013Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
CY2014Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
586442 USD
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0 USD
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
205390 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2013Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2014Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1724546 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-785171 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2013Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2014Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-361877 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2013Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2014Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11227870 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2013Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2014Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
2027930 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2013Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-19848 USD
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-17811 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
84755 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-88108 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-80146 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-836583 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2146754 USD
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-986719 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5024265 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82896311 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4990213 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8470476 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
299989 USD
snti Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4003621 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
snti Cash Paid For Fractional Shares Due To Reverse Split
CashPaidForFractionalSharesDueToReverseSplit
303 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
238904 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-68610021 USD
us-gaap Net Income Loss
NetIncomeLoss
-4191922 USD
us-gaap Net Income Loss
NetIncomeLoss
-5550725 USD
CY2013Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
150136 USD
CY2014Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2877511 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
14286290 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
798291 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2919751 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-986719 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5024265 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82896311 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4990213 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8470476 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.21
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1446420 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5806353 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1228644 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3838200 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
435988 USD
us-gaap Dividends
Dividends
29000 USD
us-gaap Noncash Contribution Expense
NoncashContributionExpense
85179 USD
us-gaap Noncash Contribution Expense
NoncashContributionExpense
0 USD
us-gaap Noncash Contribution Expense
NoncashContributionExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
131250 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
9022980 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
271831 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
115869 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
2003386 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53800 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13566623 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
39615 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
333845 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44574889 USD
snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
0 USD
snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2160986 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1227869 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
snti Gain Loss On Settlement Of Warrant Liabilities
GainLossOnSettlementOfWarrantLiabilities
-1724546 USD
snti Gain Loss On Settlement Of Warrant Liabilities
GainLossOnSettlementOfWarrantLiabilities
-785171 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1199871 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
163979 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-719349 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
5171 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
324936 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
92434 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-312384 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
876386 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2956298 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3649873 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7162110 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185947 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1281 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7348057 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-394945 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-409637 USD
snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
99728 USD
snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
0 USD
snti Proceeds From Government Grant
ProceedsFromGovernmentGrant
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-12026 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-2187082 USD
snti Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
10754841 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
651781 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
40214171 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2942981 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
10842325 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58120973 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2930955 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8655243 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6198027 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-420288 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4595733 USD
CY1998Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2001325 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1581037 USD
snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
690984 USD
snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
0 USD
snti Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
0 USD
us-gaap Interest Paid
InterestPaid
579766 USD
us-gaap Interest Paid
InterestPaid
90651 USD
us-gaap Interest Paid
InterestPaid
85629 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1 - Basis of Presentation:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The financial statements included herein have been prepared by Senesco Technologies, Inc. (the &#8220;Company&#8221;), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2013, as amended.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company&#8217;s board of directors authorized a 1:100 reverse stock split on September 30, 2013, to take effect on October 21, 2013. All share and related option and warrant information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the opinion of the Company&#8217;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of March 31, 2014 and the results of its operations for the three months and nine months ended March 31, 2014 and cash flows for the nine months ended March 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Interim results are not necessarily indicative of results for the full fiscal year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
SNTI
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6906160 shares
dei Entity Registrant Name
EntityRegistrantName
SENESCO TECHNOLOGIES INC
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
2187082 USD
snti Warrants To Purchase Of Common Stock
WarrantsToPurchaseOfCommonStock
1746666 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3493332 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure

Files In Submission

Name View Source Status
0001144204-14-029005-index-headers.html Edgar Link pending
0001144204-14-029005-index.html Edgar Link pending
0001144204-14-029005.txt Edgar Link pending
0001144204-14-029005-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snti-20140331.xml Edgar Link completed
snti-20140331.xsd Edgar Link pending
snti-20140331_cal.xml Edgar Link unprocessable
snti-20140331_def.xml Edgar Link unprocessable
snti-20140331_lab.xml Edgar Link unprocessable
snti-20140331_pre.xml Edgar Link unprocessable
v377171_10q.htm Edgar Link pending
v377171_ex10-2.htm Edgar Link pending
v377171_ex10-3.htm Edgar Link pending
v377171_ex31-1.htm Edgar Link pending
v377171_ex31-2.htm Edgar Link pending
v377171_ex32-1.htm Edgar Link pending
v377171_ex32-2.htm Edgar Link pending